Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date…
Eli Lilly (NYSE: LLY | LLY Price Prediction) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted…
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults,…
Live Updates SpaceX IPO Details, Uber Layoffs10:42am ETSpaceX has set its IPO price target at $135 per share, a figure that would place the company’s valuation in line with the record-setting numbers…
Wells Fargo’s chief agriculture economist Dr. Michael Swanson told Bloomberg Businessweek on May 29 that GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, Zepbound) will eventually match statins at roughly 90 million prescriptions, calling…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year over year, with Mounjaro at $8.66B (+125%) and Zepbound at $4.16B…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated…
CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO Price Prediction) now offers a more compelling setup than GLP-1 category…
Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth platform’s recent Novo…
Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech companies before declaring on the Invest Like the Best podcast that “2025 was…
Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings…
Live Updates Nasdaq Resilience 12:31pm ETThe Nasdaq Composite is on a historic run. The tech-heavy index has clawed back all of its losses from both the Iran war market sell-off and the…
Eli Lilly and Company (NYSE:LLY | LLY Price Prediction) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly. Lilly’s tirzepatide franchise is…
